TuHURA Biosciences Inc. (HURA)
NASDAQ: HURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
HURA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $124.90M
- EPS (TTM)
- -$0.54
- Dividend yield
- None
- 52-week range
- 0.41 – 3.43
- Day range
- 1.95 – 1.99
- Volume / Avg
- 148.97K / 250.11K
- Beta
- —
- Shares outstanding
- 63.73M
- Next earnings
- Nov 13, 2026
52-week range
HURA stock today
TuHURA Biosciences (HURA) closed at $1.96 on Oct 9, up 1.55% (+$0.03), versus the S&P 500's 0.59% gain. At this level, HURA sits in the middle of its 52-week range of $0.41 to $3.43: 42.9% below the high, set on Apr 15, 2026 and 378.0% above the low. HURA is up 155.0% year to date, outperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 26.1%.
TuHURA Biosciences has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful. TuHURA Biosciences's next earnings report is expected on Nov 13, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About TuHURA Biosciences
Company profileTuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. James A. Bianco M.D.
- Headquarters
- Tampa, FL
- Employees
- 22
- Website
- tuhurabio.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$8.04+310.20%
- Strong buy 2
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 13, 2026
TuHURA Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VTVTvTv Therapeutics Inc. Class A | 31.18 | +3.66% | $123.28M | vs HURA |
| NRXPNRX Pharmaceuticals Inc. | 2.85 | -1.38% | $123.39M | vs HURA |
| TNXPTonix Pharmaceuticals Holding Corp. | 7.30 | +0.27% | $125.20M | vs HURA |
| SPRBSpruce Biosciences Inc. | 44.05 | -3.27% | $126.60M | vs HURA |
| CLLSCellectis S.A. ADR | 1.26 | +0.80% | $126.92M | vs HURA |
| INOInovio Pharmaceuticals Inc. | 1.15 | +5.50% | $118.91M | vs HURA |
| FHTXFoghorn Therapeutics Inc. | 2.00 | +0.50% | $118.77M | vs HURA |
| COYACoya Therapeutics Inc. | 4.95 | -0.80% | $116.12M | vs HURA |
Indexes, lists and sector
TuHURA Biosciences stock FAQ
What is TuHURA Biosciences's stock price today?
HURA last traded at $1.96 as of Oct 9, 4:00 PM EDT, up 1.55% on the day. Prices are delayed at least 15 minutes.
Does TuHURA Biosciences pay a dividend?
No. TuHURA Biosciences does not currently pay a regular cash dividend.
When is TuHURA Biosciences's next earnings date?
TuHURA Biosciences is expected to report earnings on Friday, November 13, 2026.
Who is TuHURA Biosciences's CEO?
Dr. James A. Bianco M.D. is the chief executive officer of TuHURA Biosciences Inc., which has about 22 employees.
Has HURA ever split its stock?
Yes. The most recent HURA stock split was a 1-for-35 split on Oct 18, 2024, one of 3 splits on record.
What is the HURA 52-week high?
The 52-week high for HURA is $3.43 and the 52-week low is $0.41. The stock is currently 42.9% below its high.